The Sarcoma Comprehensive NGS Fusion Panel is an RNA-based next-generation sequencing panel that detects translocations and fusions with known and novel fusion partners of these genes: ACTB, AHRR, ALK, ASPSCR1, ATF1, ATIC, BCOR, BRAF, C11orf95, CAMTA1, CARS1, CCNB3, CDH11, CIC, CLTC, CNBP, COL1A1, COL1A2, CREB1, CREB3L1, CREB3L2, CSF1, CTNNB1, DDIT3, DUX4, EML4, EPC1, ERG, ETV1, ETV4, ETV6, EWSR1, FEV, FLI1, FOXO1, FRK, FUS, GLI1, HAS2, HEY1, HMGA2, IL2RB, ITK, JAZF1, LMNA, LPP, MEAF6, MRTFB, MYH9, MYLK, NAB2, NCOA1, NCOA2, NFATC2, NFIB, NR4A3, NTRK1, NTRK2, NTRK3, NUTM2A, NUTM2B, OMD, PAX3, PATZ1, PAX7, PBX1, PDGFB, PDGFRB, PHF1, PLAG1, POU5F1, RAD51B, RANBP2, ROS1, SEC31A, SRF, SS18, SSX1, SSX2, SSX4B, STAT6, SUZ12, SYK, TAF15, TCF12, TEAD1, TFE3, TFG, THRAP3, TPM3, TPM4, USP6, WT1, WWTR1, YAP1, YWHAE and ZNF444.
As of May 12, 2025, this test serves as replacement for the following test(s) that are no longer offered:
-
Ewing Sarcoma NGS Fusion Panel
-
NeoTYPE® Liposarcoma Fusion Profile
-
Non-Ewing Sarcoma NGS Fusion Panel
-
Rhabdomyosarcoma NGS Fusion Panel